Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Human or mouse-specific VEGF and soluble VEGF receptor 1, also known as soluble fms-like tyrosine kinase 1 (sFlt1), were measured by ELISA (R&D). Protein expression was assessed by Western ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

VEGF and PD-1 targeting drugs from the likes of ... in yet another signal of China's role as an emerging source of biopharma R&D innovation. A Bloomberg report indicated that the upfront payment ...

Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R ...

Nuclera agreed to collaborate with Cytiva to focus on accelerating the production, purification, and characterization of proteins needed for pharma R&D. The collaboration ... Kinase (BTK) and Vascular ...